Sudha Sreenivasan
Psychiatry New Haven, CT Medical Doctor
NPI 1942367800 CMS profile 675197
34 Park St, Connecticut Mental Health Center, New Haven, CT 06519
General payments
$542
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Sudha Sreenivasan of New Haven, CT is reported in the CMS Open Payments database as having received $542 across 30 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 61st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $17 | 1 | |
| 2020 | General | $46 | 3 | |
| 2019 | General | $480 | 26 |
Beside peers
- Sudha Sreenivasan
- Psychiatry median
- Middle half of Psychiatry
- National median
In program year 2025, general payments to Sudha Sreenivasan were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.
Show as a table
| Year | Sudha Sreenivasan | Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $480 | $184 | $59–$605 | $163 |
| 2020 | $46 | $119 | $36–$372 | $114 |
| 2021 | $17 | $143 | $43–$576 | $132 |
| 2022 | $0 | $153 | $50–$590 | $149 |
| 2023 | $0 | $170 | $56–$651 | $160 |
| 2024 | $0 | $179 | $57–$673 | $164 |
| 2025 | $0 | $180 | $58–$685 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 32 drugsPart D claims
1,353
Drug cost
$81,659
Branded share of claims
12.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Vraylar Cariprazine Hcl | Brand | 15 | $35,221 | |
| Rexulti Brexpiprazole | Brand | 11 | $16,276 | |
| Paliperidone Er Paliperidone | Brand | 25 | $7,485 | |
| Quetiapine Fumarate Er Quetiapine Fumarate | Brand | 45 | $2,677 | |
| Aripiprazole | Generic | 47 | $2,369 | |
| Divalproex Sodium Er Divalproex Sodium | Brand | 11 | $1,565 | |
| Olanzapine | Generic | 66 | $1,449 | |
| Hydroxyzine Hcl | Generic | 84 | $1,319 | |
| Fluphenazine Hcl | Generic | 13 | $1,206 | |
| Quetiapine Fumarate | Generic | 71 | $1,185 |
The 10 drugs with the highest cost, of 32 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.
Records
30 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Psychiatry in Connecticut
Related records
Psychiatry in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.